Affiliation:
1. The University of Texas at Austin Dell Medical School
Abstract
Abstract
Background Hepatitis C virus (HCV) is a leading cause of liver-related mortality and morbidity. Despite effective direct acting antivirals and a simplified treatment algorithm, limited access to HCV treatment in vulnerable populations, including people experiencing homelessness (PEH) and people who inject drugs (PWID), hinders global elimination. Adapting the evidence-based, simplified HCV treatment algorithm to the organizational and contextual realities of non-traditional clinic settings serving vulnerable populations can help overcome specific barriers to HCV care. The Erase Hep C study aimed to identify barriers and facilitators specific to these vulnerable populations to design the site-specific, simplified treatment protocols.Methods Forty-two semi-structured qualitative interviews, guided by the Practical, Robust Implementation and Suitability Model (PRISM) framework, were conducted with clinic staff, community-based organizations providing screening and linkage to care, and patients diagnosed with HCV, to identify contextual barriers and facilitators to treatment at a local community health center’s Health Care for the Homeless program in Austin, Texas. Audio-recorded interviews were systematically analyzed using thematic analysis informed by the PRISM framework and design thinking, to anchor barriers and facilitators along the HCV care cascade. Findings were fed into human-centered design workshops to co-design, with clinic staff, site-specific, simplified HCV treatment protocols.Results The specific needs of PEH and PWID patient populations informed barriers and facilitators of HCV care. Barriers included tracking patients who miss critical appointments or labs, medication access and adherence, and patient HCV knowledge. Clinical teams leveraged existing facilitators and incorporated solutions to barriers into clinic workflows to improve care coordination and medication access. Actionable solutions included augmenting existing staff roles, employing HCV care navigation throughout the cascade, and standardizing medication adherence counseling.Conclusions Clinic staff identified HCV care facilitators to leverage, and designed actionable solutions to address barriers, to incorporate into site-specific treatment protocols to improve patient HCV outcomes. Methods used to incorporate staff and patient experiential knowledge into the design of contextualized treatment protocols in non-traditional clinic settings could serve as a model for future implementation research. The next phase of the study is protocol implementation and patient enrollment into a single-arm trial to achieve HCV cure.
Publisher
Research Square Platform LLC
Reference21 articles.
1. World Health Organization, Hepatitis C, Geneva, Switzerland WHO. 2022 [updated 24 June 2022]. Available from: https://www.who.int/en/news-room/fact-sheets/detail/hepatitis-c.
2. Centers for Disease Control and Prevention, Hepatitis C. Questions and Answers for Health Professionals. Atlanta, Georgia: CDC, 2020 [updated August 7, 2020]. Available from: https://www.cdc.gov/hepatitis/hcv/hcvfaq.htm#section1.
3. Toward a more accurate estimate of the prevalence of hepatitis C in the United States;Edlin BR;Hepatology,2015
4. Hepatitis C among clients of health care for the homeless primary care clinics;Strehlow AJ;J Health Care Poor Underserved,2012
5. The treatment cascade for chronic hepatitis C virus infection in the United States: a systematic review and meta-analysis;Yehia BR;PLoS ONE,2014